Skip to main content

Neurocrine Biosciences, Inc. (NBIX)

NASDAQ: NBIX · IEX Real-Time Price · USD
95.57 -0.94 (-0.97%)
Sep 20, 2021 11:10 AM EDT - Market open
Market Cap9.13B
Revenue (ttm)1.03B
Net Income (ttm)364.70M
Shares Out94.60M
EPS (ttm)3.72
PE Ratio25.72
Forward PE21.98
Dividendn/a
Ex-Dividend Daten/a
Volume121,713
Open94.87
Previous Close96.50
Day's Range94.11 - 95.62
52-Week Range84.77 - 120.27
Beta0.73
AnalystsBuy
Price Target122.19 (+27.9%)
Est. Earnings DateNov 8, 2021

About NBIX

Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methylt...

IndustryBiotechnology
IPO DateMay 23, 1996
CEOKevin Gorman
Employees884
Stock ExchangeNASDAQ
Ticker SymbolNBIX
Full Company Profile

Financial Performance

In 2020, NBIX's revenue was $1.05 billion, an increase of 32.71% compared to the previous year's $788.10 million. Earnings were $407.30 million, an increase of 1,000.81%.

Financial Statements

Analyst Forecast

According to 25 analysts, the average rating for NBIX stock is "Buy." The 12-month stock price forecast is 122.19, which is an increase of 27.86% from the latest price.

Price Target
$122.19
(27.86% upside)
Analyst Consensus: Buy

News

Neurocrine Biosciences to Present New INGREZZA® (valbenazine) and ONGENTYS® (opicapone) Data at the MDS Virtual Congr...

SAN DIEGO, Sept. 10, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data from its movement disorder treatments for tardive dyskinesia (TD) and ...

1 week ago - PRNewsWire

Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

SAN DIEGO, Sept. 2, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following virtual investor conferences: K...

2 weeks ago - PRNewsWire

11 Mighty Mid-Cap Stocks for the Rest of 2021

Want more stability and greater growth prospects in your investments? These top-rated mid-cap stocks offer the best of both worlds.

1 month ago - Kiplinger

Neurocrine Biosciences Announces Completion of Enrollment in Phase 3 KINECT-HD Study Evaluating Valbenazine for Chore...

SAN DIEGO, Aug. 5, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), in collaboration with the Huntington Study Group, today announced the completion of patient enrollment for its Phase ...

1 month ago - PRNewsWire

Neurocrine Biosciences (NBIX) Q2 Earnings Miss Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of -17.31% and 5.26%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Neurocrine Biosciences Reports Second Quarter 2021 Financial Results

SAN DIEGO, Aug. 3, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2021. "We helped more tardive dyskinesia p...

1 month ago - PRNewsWire

Analysts Estimate Neurocrine Biosciences (NBIX) to Report a Decline in Earnings: What to Look Out for

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results

SAN DIEGO, July 19, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter 2021 financial results after the Nasdaq market closes on Tuesday, ...

2 months ago - PRNewsWire

Neurocrine Biosciences to Participate at the William Blair Biotech Focus Conference

SAN DIEGO, July 8, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Kyle Gano, Chief Business Development and Strategy Officer, will participate in a neuropsychology...

2 months ago - PRNewsWire

Sarepta, Vertex, Neurocrine: There's Deep Value In These Beaten Down Healthcare Stocks

Our theme of Out Of Favor Health Care Stocks includes healthcare and pharma names that are seeing a disconnect between their financial performance and stock price returns. Specifically, the theme filter...

Other symbols:SRPT
2 months ago - Forbes

BofA Securities Makes Big Summer Changes to US 1 List of Top Stock Picks

With the second quarter of 2021 all but over and the latter half of 2021 right around the corner, many of the top companies we follow on Wall Street are making some changes to their lists of high-convic...

Other symbols:ATVIEQIXFDXUNP
2 months ago - 24/7 Wall Street

Neurocrine Biosciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

SAN DIEGO, June 1, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference at 1:20 p.m. Eastern Time on Tuesday, June ...

3 months ago - PRNewsWire

Neurocrine Biosciences to Present at the 2021 RBC Global Healthcare Conference

SAN DIEGO, May 11, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 2021 RBC Capital Markets Healthcare Conference at 10:55 a.m. Eastern Time on Tuesday May 18, 2021.

4 months ago - PRNewsWire

Neurocrine Biosciences (NBIX) Q1 Earnings and Revenues Miss Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of -29.79% and -4.52%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Neurocrine Biosciences Reports First Quarter 2021 Financial Results

SAN DIEGO, May 5, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2021 and provided revised full-year 2021 fi...

4 months ago - PRNewsWire

Neurocrine Biosciences to Present at the Bank of America 2021 Healthcare Conference

SAN DIEGO, May 4, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America 2021 Healthcare Conference at 11:00 a.m. Eastern Time on Tuesday May 11, 2021.

4 months ago - PRNewsWire

Neurocrine Biosciences Supports Mental Health Month and Tardive Dyskinesia Awareness Week

SAN DIEGO, May 3, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its support of Mental Health Month and commitment to raising awareness of and supporting people living ...

4 months ago - PRNewsWire

Analysts Estimate Neurocrine Biosciences (NBIX) to Report a Decline in Earnings: What to Look Out for

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Neurocrine Biosciences Announces Appointment of Johanna Mercier to Board of Directors

SAN DIEGO, April 16, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Johanna Mercier to its Board of Directors. Ms. Mercier is the Chief Commercial Of...

5 months ago - PRNewsWire

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2021 Financial Results

SAN DIEGO, April 14, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report first quarter 2021 financial results after the Nasdaq market closes on Wednesday...

5 months ago - PRNewsWire

Neurocrine Biosciences to Present Data from its Neurology Portfolio at the American Academy of Neurology's 73rd 2021 ...

SAN DIEGO, April 8, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data from its movement disorders and epilepsy programs at the American Academy o...

5 months ago - PRNewsWire

Strength Seen in Neurocrine (NBIX): Can Its 11.1% Jump Turn into More Strength?

Neurocrine (NBIX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

5 months ago - Zacks Investment Research

Neurocrine Biosciences to Present at Stifel 3rd Annual CNS Day

SAN DIEGO, March 25, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 3rd Annual CNS Day at 12:30 p.m. Eastern Time on Thursday Apr. 1, 2021.

5 months ago - PRNewsWire

Why Neurocrine Biosciences Stock Jumped Today

The stock is being added to a mid-cap index.

5 months ago - The Motley Fool

Neurocrine Biosciences Set to Join S&P MidCap 400; O-I Glass to Join S&P SmallCap 600

NEW YORK, March 24, 2021 /PRNewswire/ -- Neurocrine Biosciences Inc. (NASD:NBIX) will replace O-I Glass Inc. (NYSE:OI) in the S&P MidCap 400, and O-I Glass will replace HMS Holdings Corp (NASD:HMSY) in ...

Other symbols:OI
5 months ago - PRNewsWire